"Step-down" therapy for asthma: Why, when, and how?

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 6, 2002, Pages 916-919

  Bacharier, Leonard B ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

"step down"; Asthma therapy

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; MONTELUKAST; NITRIC OXIDE; PRANLUKAST; SALMETEROL;

ASTHMA; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG SAFETY; DRY POWDER; EDITORIAL; HUMAN; PATIENT SATISFACTION; POWDER INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT PLANNING;

EID: 0036283253     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.124665     Document Type: Article

References (24)

1. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone
2. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
3. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
4. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIAS-MA)
5. Montelukast added to inhaled beclomethasone in treatment of asthma
6. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
7. Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: Impact of budesonide treatment and withdrawal
8. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration
9. Long-term effects of budesonide or nedocromil in children with asthma
10. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
11. Reduction of budesonide after a year of increased use: A randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained
12. Initial loading (400 micrograms twice daily) versus static (400 micrograms nocte) dose budesonide for asthma management
13. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height
14. Potential masking effects of salmeterol on airway inflammation in asthma
15. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial
16. Effect of long-term treatment with salmeterol on asthma control: A double blind, randomised crossover study
17. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics
18. Does salmeterol facilitate "step-down" therapy in patients with asthma receiving moderate to high doses of inhaled corticosteroids?
19. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
20. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
21. Treatment of allergic asthma with monoclonal anti-IgE antibody
22. The long-acting beta2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma